NCT02957396 - Study of Finerenone to Investigate a Paediatric Formulation in Healthy Male Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 17, 2016

Primary Completion Date

January 13, 2017

Study Completion Date

March 1, 2017

Conditions

Pharmacokinetics

Interventions

DRUG

Finerenone (BAY94-8862): 20 mg intact tablet

20 mg intact finerenone immediate-release tablet; single dose in the fasting condition

DRUG

Finerenone (BAY94-8862): 20 mg crushed and resuspended tablet

20 mg crushed and resuspended finerenone immediate-release tablet; single dose in the fasting condition

DRUG

Finerenone (BAY94-8862): 20 mg suspension

20 mg finerenone suspension; single dose in the fasting condition or in the fed condition

Trial Locations (1)

Berlin